Ocugen Inc.

Ocugen builds advanced gene therapies, with Phase‑3 OCU400 for inherited retinal disease, Phase‑1/2 OCU410/410ST for AMD and Stargardt, and cartilage repair NeoCart. It also develops COVID‑19 and flu vaccines, partnering CanSino and NIAID.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 95
HQ: Malvern

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
OCGN	Ocugen Inc. Cap: 0.5B	EQUITY	NMS	USD	US67577C1053	Active	📈